Arlin Z, Kempin S, Mertelsmann R, Gee T, Higgins C, Jhanwar S, Chaganti R S, Clarkson B
Blood. 1984 Jan;63(1):211-2.
Remission rates for patients with acute promyelocytic leukemia (APL) have improved with the use of anthracyclines and proper management of disseminated intravascular coagulopathy. In a prospective randomized trial of chemotherapy in patients with acute nonlymphoblastic leukemia, there were 16 patients with APL. All 7 of the patients receiving the amsacrine-containing regimen and 5 of 9 receiving the daunorubicin-containing regimen achieved a remission. All patients, except 2 of the 3 who underwent bone marrow transplantation, remain alive and in remission from 1+ to 25+ mo. Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL.
通过使用蒽环类药物以及对弥散性血管内凝血进行适当管理，急性早幼粒细胞白血病（APL）患者的缓解率有所提高。在一项针对急性非淋巴细胞白血病患者的化疗前瞻性随机试验中，有16例APL患者。接受含安吖啶方案的所有7例患者以及接受含柔红霉素方案的9例中的5例实现了缓解。除3例接受骨髓移植的患者中有2例之外，所有患者均存活且缓解状态持续了1个月以上至25个月以上。安吖啶在APL治疗中是柔红霉素的有效替代药物，并且其使用不会影响APL特有的良好缓解持续时间。
